Psoriasis
Pipeline by Development Stage
Drug Modality Breakdown
Psoriasis is a ~$900M Part D market dominated by a single peak-stage drug, with modest growth from emerging IL-17 and next-gen mechanisms.
Key Trends
- OTEZLA (apremilast) monopolizes 98% of spending despite aging lifecycle
- Emerging IL-17 antagonists and next-generation biologics entering at smaller scale
- Topical corticosteroids and vitamin D analogs represent legacy commodity segment
Career Verdict
Psoriasis offers moderate career opportunity: stable revenue base but limited growth upside and heavy dependence on a single aging asset; best suited for professionals seeking a mature, predictable immunology niche rather than high-growth dynamism.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | OTEZLA (apremilast) | Bristol Myers Squibb | $877M | 98% | Peak | Stable | |
| 2 | SILIQ (brodalumab) | Bausch + Lomb | $10M | 1% | Peak | Stable |
Drug Class Breakdown
stable; OTEZLA dominance sustained
early entry; niche positioning
declining; loss-of-exclusivity approaching
stable; legacy segment
Career Outlook
StablePsoriasis represents a defensible, mature indication with predictable revenue ($900M+) anchored by a single dominant therapy. However, limited pipeline blockbuster potential and commodity-level competition in topical segments mean career growth depends on commercial optimization and new-patient access rather than breakthrough innovation. Suitable for professionals seeking stability and operational mastery over venture-scale upside.
Breaking In
Entry-level candidates should target Medical Affairs, Clinical Operations, or Commercial Analytics roles at BMS, Amgen, or AbbVie to build immunology disease expertise and patient insight in a low-turbulence environment.
For Experienced Professionals
Experienced oncology/immunology professionals may find psoriasis a lower-stakes sandbox for P&L leadership, but should weigh limited innovation upside against the stability of a $900M revenue base held by a single company.
In-Demand Skills
Best For
Hiring Landscape
Psoriasis-specific hiring is modest; the 6,799 total jobs reported reflects broader immunology/dermatology ecosystem rather than psoriasis-alone staffing. Top employers (Bristol Myers Squibb, Amgen, AbbVie) are large conglomerates hiring across multiple indications. Commercial roles dominate, reflecting mature market dynamics and extensive patient-engagement infrastructure.
Top Hiring Companies
By Department
Hiring is concentrated in commercial and manufacturing roles; limited R&D positions; best opportunity for sales force, reimbursement, and patient support specialists in a stable but not high-growth market.
On Market (3)
Approved therapies currently available
Competitive Landscape
86 companies ranked by most advanced pipeline stage
+56 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 49 trials with date data
Clinical Trials (50)
Total enrollment: 7,532 patients across 50 trials
Enbrel® in Psoriatic Arthritis
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
Brain Changes in Psoriasis After Secukinumab Treatment
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
Taltz in Combination With Enstilar for Psoriasis
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Danish Population-based Assessment of Psoriasis and Psoriatic Arthritis (DANPAPP)
Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
Enstilar in Combination With Biologic Agents
Vascular Inflammation in Psoriasis - Apremilast
Immunologic Response to Secukinumab in Plaque Psoriasis
Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy
Proton Pump Inhibitors Use in Patients With Psoriasis
A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate
Vascular Inflammation in Psoriasis - Extension Study
A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis
Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?
Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam
A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
A Study to Evaluate the Efficacy and Safety of LZM012
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Related Jobs in Immunology
Executive Medical Director, Clinical Development
Director, Thought Leader Liaison, US Psoriasis Launch
Senior Scientific Communications Manager
Senior Publications Manager
Senior Manager, Clinical Supply Chain (Biologics)
Trial Master File (TMF) Manager
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.